Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

Preoperative use of GLP-1 receptor agonists was not significantly associated with short-term postoperative aspiration ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

GLP-1 medications like Ozempic are reshaping the way people snack, with fewer ultra-processed foods and a shift toward nutrient-packed bites. See what’s in and what’s out.